Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032592 | 0.82 | TGFBR1 (0.55) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4569965 | 0.81 | RAB9A (0.68) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL29496949 | 0.81 | RAB9A (0.68) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL29496952 | 0.81 | RAB9A (0.68) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4029750 | 0.79 | TGFBR1 (0.47) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4029975 | 0.79 | MAPT (0.42) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4032928 | 0.79 | KDM4E (0.44) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4032916 | 0.77 | TGFBR1 (0.40) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4032644 | 0.77 | TGFBR1 (0.46) | MAPTNPC1POLBTGFBR1MAPK13 | |
| SCHEMBL6600949 | 0.75 | RAB9A (0.54) | MAPTRAB9ANPC1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1542994-A1 | NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026863-A1 | NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | MAPT 1874/4885RAB9A 4469/4885NPC1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.